ERCC1对晚期非小细胞肺癌一线含铂化疗疗效的预测价值

宁晓红; 王毓洲; 孙昭; 李霁; 周艳萍; 白春梅

ERCC1对晚期非小细胞肺癌一线含铂化疗疗效的预测价值

Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer

摘要

摘要:
目的探讨肺癌组织ERCC1(excision repair cross-complementation group1)表达水平对晚期非小细胞肺癌含铂化疗疗效及生存期的预测价值。
方法采用免疫组织化学方法对39例非小细胞肺癌患者的石蜡包埋肿瘤标本进行ERCC1检测, 分析其与化疗反应率及生存期间的关系。
结果 56.4%(22/39)的肿瘤组织呈ERCC1高表达。ERCC1表达与患者性别、年龄、病理类型、肿瘤分化程度、吸烟史及吸烟指数均无相关性; ERCC1低表达患者对含铂一线化疗的反应率优于ERCC1高表达者, P < 0.05。但ERCC1表达水平对患者总生存(overall survival, OS)和疾病进展(time to progression, TTP)时间没有明显影响。
结论 ERCC1在肺癌组织的表达水平可能成为预测晚期非小细胞肺癌患者一线含铂化疗方案疗效的因素之一。

Abstract:
Objective To explore the role of expression of excision repair cross-complementation group 1 (ERCC1) in predicting the outcomes of platinum-based chemotherapy in patients with end-stage non-small-cell lung cancer.
Methods The expression of ERCC1 was detected with immunohistochemical methods in paraffin-embeded tumor specimens obtained from 39 patients with chemo-naive non-small-cell lung cancer. The relationship between ERCC1 expression and the response rate of platinum-based chemotherapy as well as its possible values in predicting overall survival (OS) and time to progression (TTP) were analyzed.
Results ERCC1 was highly expressed in 39 tumors (56.4%). The expression of ERCC1 showed no association with gender, age, pathologic type, grade of differentiation, smoking history, and smoking index. The response rate of platinum-based chemotherapy was significantly higher in patients with low ERCC1 expression (P < 0.05). Furthermore, ERCC1 expression had no notable influence on OS and TTP.
Conclusion The expression of ERCC1 in lung tumor may be useful in predicting the effectiveness of platinum-based chemotherapy for end-stage non-small-cell lung cancer.

HTML全文

参考文献(14)

施引文献

资源附件(0)